October 2026 | Q2FY27 Results, Company Deep Dives, Healthcare Regulation & AI Infrastructure

📊 Q2FY27 Results — Key Prints

TVS Motor — Broad-Based Growth and Margin Expansion:

Revenue grew 44% YoY, EBITDA 47% and PAT 52%. EBITDA margin improved to 13%, approximately 30 basis points above the previous year.
Strong operating performance was supported by domestic two-wheeler demand, exports and electric vehicles.
Earnings exceeded consensus estimates by approximately 5% at the revenue level and 8% at EBITDA and PAT levels.
The combination of volume growth, operating leverage and premiumisation remains central to the earnings trajectory.

Sona BLW — EV Growth Accelerates:

Revenue grew 35% YoY and PAT 29%, ahead of broker estimates.
Battery electric vehicle revenue grew 129% YoY and reached 51% of automotive revenue.
Quarterly order intake of approximately ₹3,600 crore was the highest recorded, supported by new EV and conventional powertrain programmes.
EBITDA margin of 23% was below expectations, partly reflecting product mix, particularly faster growth in lower-margin traction motors, alongside input and freight costs.
The order book provides visibility, but margins and cash conversion remain important measures of execution.

Polycab / KEI — Strong Results Despite Competitive Concerns:

Polycab reported revenue growth of 53%, EBITDA growth of 39% and PAT growth of 43%. Results were materially ahead of consensus expectations.
KEI reported approximately 39% revenue and EBITDA growth and 29% PAT growth. Despite the strong growth, its EBITDA margin of roughly 10% was below the approximately 11% consensus expectation.
The new Ultravolt business has rapidly developed distribution infrastructure and production capacity, increasing the prospective intensity of competition in the wires market.
Polycab management indicated that it saw no immediate need for defensive price reductions.
Key question: Can incumbent manufacturers sustain strong volume growth while defending margins and distribution share as a well-capitalised competitor scales up?

Acutaas Chemicals — Strong Operating Growth and Improved Cash Generation:

Q2FY27 revenue rose 42.7% YoY to approximately ₹437 crore.
Calculated EBITDA, excluding other income, grew approximately 85% YoY, with an estimated margin of 40.3% versus 31.1% a year earlier.
Reported consolidated PAT increased approximately 71% YoY.
H1 operating cash flow of approximately ₹216 crore exceeded capital expenditure of ₹124 crore, providing support for the reported earnings growth.
Management’s revised CDMO ambition of ₹1,000 crore revenue by FY27, compared with its earlier FY28 timeline, suggests faster expected scaling.
Semiconductor chemicals and battery additives remain longer-term diversification opportunities. Diligence centres on margin sustainability, CDMO visibility and ramp-up of newer facilities.

Mankind Pharma — Domestic Performance Improves:

PAT exceeded two broker estimates by approximately 15%.
Domestic growth outperformed the Indian pharmaceutical market by approximately one percentage point after four consecutive quarters of underperformance.
Four of the seven largest therapy categories outperformed their respective markets.
Anti-infectives continued to underperform, although their relative trajectory was improving.
Further evidence of sustained market outperformance will be important.

Bajaj Finance — Earnings Growth With Credit-Cost Qualifications:

PAT grew approximately 29% YoY, broadly in line with market estimates.
Reported loan losses and provisions included a ₹337 crore management and macroeconomic overlay.
Excluding the overlay, underlying loan losses declined compared with the corresponding previous-year quarter.
Management commentary pointed to improving credit-cost expectations, although MSME asset quality and changes in gold-loan regulations require continued monitoring.
The distinction between reported credit costs, precautionary provisions and underlying delinquencies remains important.

Other Results — Quick Takes:

APL Apollo: Revenue broadly in line; EBITDA and PAT 9% and 7% ahead of consensus. EBITDA per tonne came in at approximately ₹6,000 versus ₹5,500 expected.
Concord Biotech: Revenue grew 25%, EBITDA 18% and PBT 15%. Gross-margin performance and JV-related losses moderated PAT growth.
Havells: Revenue grew 35% and EBITDA approximately 30%. Wires and cables recorded strong top-line growth but weaker EBIT conversion.
Tatva Chintan: Revenue grew 75%, EBITDA 80% and PAT 116%. Negative operating cash flow due to working-capital absorption remains a qualification.
Aeroflex: Strong earnings were accompanied by a change in PPE depreciation methodology. Internal adjustments suggest PAT growth closer to 100% versus reported 158%, underscoring accounting vs operating divergence.

🔬 Company Deep Dives

Ather Energy — The Improvement Beneath the Hardware Economics:

Separated core vehicle hardware economics from higher-margin software, ecosystem revenue and government incentives.
Direct-material gross profit per scooter improved from approximately negative ₹950 in FY24 to positive ₹17,635 in Q2FY27.
On this methodology, vehicle hardware gross margin improved to approximately 13.2%.
After excluding both software and subsidies, estimated underlying hardware gross margin improved from negative 31.2% in FY23 to positive 11.1% in Q2FY27.
This reconstructed metric indicates significant unit-economic improvement, though overall profitability still hinges on fixed costs, distribution overhead and operating scale.

Unimech Aerospace — Order Visibility Versus Working-Capital Intensity:

Q2FY27 revenue grew approximately 100% YoY, with the consolidated order book expanding nearly eightfold to ~₹855 crore.
Pipeline comprises ₹266 crore in confirmed POs and ₹589 crore in long-term agreements/award letters, each carrying different revenue certainty.
Excluding Hobel Bellows, quarterly growth moderated to ~22% from 36% in Q1FY27.
Working-capital days stood at ~110, with management maintaining full-year guidance of 150–160 days.
Proposed early CY27 fundraising and rising depreciation from capacity expansion could weigh on per-share metrics and cash generation.

Sterlite Technologies — AI Fibre Demand Meets Financing Risk:

Management highlighted industry forecasts upgrading expected 2026 data-centre optical-fibre demand growth from 63% to 89% (specific to data-centre fibre, not broad industry demand).
Hyperscaler contracts and long-term agreements provide demand visibility, supplemented by telecom and neutral-fibre customers.
Principal risks include AI infrastructure funding availability, project delays, supply additions, pricing power and demand durability post-buildout.
A strong order environment does not automatically guarantee attractive shareholder returns at any entry valuation.

Sky Gold — Cash Conversion Takes Centre Stage:

Management guided FY27 operating cash flow to ₹180–225 crore, reversing negative cash flows reported across FY25 and FY26.
Targeting net debt reduction to ₹200–250 crore by March 2027, down from ₹549 crore in March 2026, driven by operating cash flow and land monetisation.
Increasing use of customer-supplied gold could ease working-capital demands.
Progress should be judged strictly on recurring operating cash generation, stripping out non-recurring asset sales.

Data Patterns — Execution Quality Versus Order-Conversion Timing:

Maintains a robust multiyear track record of top-line and EBITDA growth with industry-leading operating margins.
Order inflows remain lumpy due to government approvals, procurement cycles and milestone certifications.
Management reiterated FY27 revenue growth guidance of 20–25% with EBITDA margins of 35–40%.
Diligence must differentiate between negotiated opportunities, confirmed orders and realised revenue conversion.

🏥 Healthcare & Pharmaceuticals — Regulation Becomes More Specific

Cancer Drug Trade-Margin Caps — From Proposal to Notification:

NPPA notified a 30% trade-margin cap across 137 non-scheduled anti-cancer drugs on October 17, 2026, taking effect November 9, 2026.
Potential patient MRP cuts could reach up to 70%, depending on baseline pricing frameworks.
The intervention primarily curtails distribution and hospital retail spreads rather than imposing blanket reductions on manufacturer realisations.
Financial impact will diverge widely across oncology manufacturers, hospital operators and stockists based on formulary mix and procurement contracts.

HCG and Hospital Pharmacy Economics:

Oncology drugs and consumables represent a disproportionate share of hospital operating margins.
Earnings exposure cannot be evaluated simply via medical-oncology revenue share, as drug purchase discounts, billing schedules and service margins vary materially.
Scenario analysis flags potential EBITDA margin compression, but concrete assessment requires portfolio-level trade data. Broader non-oncology margin caps remain an unconfirmed policy overhang.

Beta Drugs — Management Sees Limited Direct Impact:

FY26 branded oncology portfolio included ~₹60 crore in oral formulations and ~₹50 crore in scheduled injectables, neither exposed to the new order.
The remaining ~₹13 crore of non-scheduled injectables is expected to see negligible earnings impact.
Demonstrates why generic policy headlines yield contrasting bottom-line consequences between pure manufacturers and dispensing hospitals.

🌐 Sector & Thematic Research

NBFC Credit Quality — Early Delinquencies Matter:

Cholamandalam saw modest sequential Stage 3 easing (3.29% to 3.25%), alongside slightly better GNPA/NNPA prints.
MAS Financial saw Stage 2 rise from 2.01% to 2.07% and Stage 3 from 2.58% to 2.64% between June and September.
Trends across Shriram Finance and AU Small Finance Bank confirm divergence in early bucket movements.
Underwriting discipline, fuel dynamics, rural cash flows and borrower mix mean performance cannot be generalised across lenders. Segmental 30/60/90 DPD tracking remains critical.

AI Infrastructure — Strong Demand, But Who Earns the Return?:

Framework separates infrastructure capex, cloud provider revenues and downstream end-user software spend.
Modelling suggests hundreds of billions in incremental cloud revenues and up to ~$1 trillion in application spending may be required to generate hurdle-rate returns across current build-out schedules.
Rapid adoption can coexist with depressed provider cash flows due to steep GPU depreciation, financing burdens and compressed hardware refresh cycles.
Collapsing inference costs boost token volumes without guaranteeing commensurate revenue growth.

IT Services — AI Decouples Headcount From Revenue:

Automation poses deflationary risks to traditional time-and-material billing models by compressing required billable hours.
Growth tailwinds tilt toward fixed-price engagements, managed AI workflows, and dedicated AI engineering.
HCLTech highlighted expanding advanced-AI deal flow, while peers noted internal operational efficiencies.
Key dilemma: Determining whether productivity dividends flow to vendor margins or are competed away to enterprise clients.

Crude Oil and Refining — Supply Bottlenecks vs Demand Destruction:

Refining capacity bottlenecks can keep crack spreads and product margins elevated even as upstream crude supply normalises.
Key monitors: regional refining spreads, run-rates and product inventories across integrated vs standalone refiners.
Prolonged high refined prices increase the risk of demand destruction over medium-term horizons.

📈 Valuation & Emerging Research Screens

Yash Highvoltage:

Supported by transformer-bushing demand tailwinds, margin expansion and moderating capex. Multiples scenario indicates ~25% annualised return potential at a forward PEG < 1, assuming sustained cash conversion.

Sai Life Sciences:

Highlighted wide discrepancies between P/E and EV/EBITDA projections. Cross-comparison with Anthem Biosciences highlights variances in ROIC and operating leverage, cautioning against revenue-only screening.

Eris Lifesciences:

Low PEG screening proved deceptively cheap; trailing Indian pharma market growth and valuation de-rating underline the pitfalls of relying on low PEG without operational momentum.

CP PLUS / Aditya Infotech:

Demanding PEG multiples paired with component cost pressures. Capacity reallocation toward AI memory and chips presents an ongoing component supply risk.

Other Research Screens:

Amber Enterprises: Attractive forecast PAT growth drives a low forward PEG; earnings quality and durability require verification.
Pricol: Historical-multiple reversion models indicate attractive upside, contingent on margin execution.
PG Electroplast: Favourable optical multiples warrant caution pending deeper component-level margin validation.
Wendt India: Rebound in quarterly run-rates reignites interest in its specialised industrial abrasive exposure.

🎯 Concluding Observations

Growth vs Valuation: Robust operating beats do not guarantee performance when multiple compression or market expectations run ahead of fundamentals.
Earnings vs Cash Flow: Working-capital expansion, capitalisation adjustments, provisioning overlays and non-recurring disposals must be scrubbed from core cash earnings.
Sector Tailwinds vs Micro Economics: Secular themes (AI, EV, defence, oncology) do not automatically insulate businesses lacking pricing power or capital return discipline.
Regulation vs Exposure: Headline policy interventions require granular SKU and distribution mapping before extrapolating margin damage.

Disclaimer: Summarised from internal investment research and observations as of October 29, 2026. Forward-looking scenarios and screens do not constitute investment recommendations.